STAT April 25, 2024
Andrew Joseph

LONDON — Claire Booth, a gene therapy researcher in London, had hoped that a biotech company would take her team’s work on an experimental medication for an ultra-rare children’s disease and get it to market. It didn’t happen.

Now, in an unusual step, the hospital where she works is trying to get the medicine approved on its own.

Booth, who leads the stem cell gene therapy program at London’s Great Ormond Street Hospital...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Health System / Hospital, Pharma / Biotech, Provider
Opinion: Readers respond to funding academic medical centers, the ‘residency research arms race,’ and more
Hospitals could see more financial pressure from ban of non-compete agreements, Fitch Ratings says
Cybersecurity and hospitals: Big risks come from third parties
Hospitals face financial hurdles as costs rise, reimbursements lag
Providence Spins Out Praia Health with $20M in Oversubscribed Series A Funding Led by Frist Cressey Ventures to Scale New Consumer Platform for Health Care

Share This Article